{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:24:19Z","timestamp":1783524259771,"version":"3.55.0"},"reference-count":51,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,11,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Drug-induced acute hemolytic anemia led to the discovery of G6PD deficiency. However, most clinical data are from isolated case reports. In 2 clinical trials of antimalarial preparations containing dapsone (4,4\u2032-diaminodiphenylsulfone; 2.5 mg\/kg once daily for 3 days), 95 G6PD-deficient hemizygous boys, 24 G6PD-deficient homozygous girls, and 200 girls heterozygous for G6PD deficiency received this agent. In the first 2 groups, there was a maximum decrease in hemoglobin averaging \u22122.64 g\/dL (range \u22126.70 to +0.30 g\/dL), which was significantly greater than for the comparator group receiving artemether-lumefantrine (adjusted difference \u22121.46 g\/dL; 95% confidence interval \u22121.76, \u22121.15). Hemoglobin concentrations were decreased by \u2265 40% versus pretreatment in 24\/119 (20.2%) of the G6PD-deficient children; 13\/119 (10.9%) required blood transfusion. In the heterozygous girls, the mean maximum decrease in hemoglobin was \u22121.83 g\/dL (range +0.90 to \u22125.20 g\/dL); 1 in 200 (0.5%) required blood transfusion. All children eventually recovered. All the G6PD-deficient children had the G6PD A\u2212 variant, ie, mutations V68M and N126D. Drug-induced acute hemolytic anemia in G6PD A\u2212 subjects can be life-threatening, depending on the nature and dosage of the drug trigger. Therefore, contrary to current perception, in clinical terms the A\u2212 type of G6PD deficiency cannot be regarded as mild. This study is registered at http:\/\/www.clinicaltrials.gov as NCT00344006 and NCT00371735.<\/jats:p>","DOI":"10.1182\/blood-2012-03-416032","type":"journal-article","created":{"date-parts":[[2012,9,19]],"date-time":"2012-09-19T22:42:16Z","timestamp":1348094536000},"page":"4123-4133","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":104,"title":["Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase\u2013deficient children receiving dapsone"],"prefix":"10.1182","volume":"120","author":[{"given":"Allan","family":"Pamba","sequence":"first","affiliation":[{"name":"GlaxoSmithKline, Brentford, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi D.","family":"Richardson","sequence":"additional","affiliation":[{"name":"Magenta Communications Ltd, Abingdon, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Carter","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Stockley Park West, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Duparc","sequence":"additional","affiliation":[{"name":"Medicines for Malaria Venture, Geneva, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zul","family":"Premji","sequence":"additional","affiliation":[{"name":"Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred B.","family":"Tiono","sequence":"additional","affiliation":[{"name":"Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucio","family":"Luzzatto","sequence":"additional","affiliation":[{"name":"Istituto Toscano Tumori (ITT), Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5","key":"2019111809170678700_B1","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1182\/blood.V54.5.961.bloodjournal545961","article-title":"Genetics of red cells and susceptibility to malaria.","volume":"54","author":"Luzzatto","year":"1979","journal-title":"Blood"},{"issue":"5529","key":"2019111809170678700_B2","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1126\/science.1063292","article-title":"Malaria. Protecting against bad air.","volume":"293","author":"Luzzatto","year":"2001","journal-title":"Science"},{"key":"2019111809170678700_B3","first-page":"28","article-title":"Metabolic polymorphisms and the role of infectious diseases in human evolution.","volume":"32","author":"Motulsky","year":"1960","journal-title":"Hum Biol"},{"issue":"3","key":"2019111809170678700_B4","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.bcmd.2008.12.005","article-title":"The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis.","volume":"42","author":"Nkhoma","year":"2009","journal-title":"Blood Cells Mol Dis"},{"issue":"4","key":"2019111809170678700_B5","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1093\/genetics\/162.4.1849","article-title":"Nucleotide variability at G6pd and the signature of malarial selection in humans.","volume":"162","author":"Saunders","year":"2002","journal-title":"Genetics"},{"issue":"7742","key":"2019111809170678700_B6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0140-6736(72)90676-9","article-title":"Glucose-6-phosphate dehydrogenase and malaria. Greater resistance of females heterozygous for enzyme deficiency and of males with non-deficient variant.","volume":"1","author":"Bienzle","year":"1972","journal-title":"Lancet"},{"issue":"8","key":"2019111809170678700_B7","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/ejhg.2009.8","article-title":"Allelic heterogeneity of G6PD deficiency in West Africa and severe malaria susceptibility.","volume":"17","author":"Clark","year":"2009","journal-title":"Eur J Hum Genet"},{"issue":"3","key":"2019111809170678700_B8","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1371\/journal.pmed.0040066","article-title":"X-linked G6PD deficiency protects hemizygous males but not heterozygous females against severe malaria.","volume":"4","author":"Guindo","year":"2007","journal-title":"PLoS Med"},{"key":"2019111809170678700_B9","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1093\/med\/9780199204854.003.220512","article-title":"Glucose-6-phosphate dehydrogenase (G6PD) deficiency.","volume-title":"Oxford Textbook of Medicine","author":"Luzzatto","year":"2010"},{"key":"2019111809170678700_B10","first-page":"883","article-title":"Glucose 6-phosphate dehydrogenase deficiency.","volume-title":"Hematology of Infancy and Childhood","author":"Luzzatto","year":"2009"},{"issue":"3220","key":"2019111809170678700_B11","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1126\/science.124.3220.484-a","article-title":"Enzymatic deficiency in primaquine-sensitive erythrocytes.","volume":"124","author":"Alving","year":"1956","journal-title":"Science"},{"issue":"2","key":"2019111809170678700_B12","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1182\/blood.V14.2.103.103","article-title":"The hemolytic effect of primaquine and related compounds: a review.","volume":"14","author":"Beutler","year":"1959","journal-title":"Blood"},{"key":"2019111809170678700_B13","unstructured":"BNF Joint Formulary Committee British National Formulary 2010-2011 Accessed July 1, 2011 London, United Kingdom Royal Pharmaceutical Society http:\/\/bnf.org\/bnf\/bnf\/current\/index.htm"},{"issue":"9","key":"2019111809170678700_B14","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2165\/11536520-000000000-00000","article-title":"Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review.","volume":"33","author":"Youngster","year":"2010","journal-title":"Drug Saf"},{"key":"2019111809170678700_B15","unstructured":"Roll Back Malaria The use of antimalarial drugs: report of an informal consultation 2001 Accessed April 8, 2011 Geneva, Switzerland World Health Organization http:\/\/www.rbm.who.int\/cmc_upload\/0\/000\/014\/923\/am_toc.htm#toc"},{"issue":"11","key":"2019111809170678700_B16","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1046\/j.1365-3156.2001.00751.x","article-title":"Chlorproguanil-dapsone (LAPDAP) for uncomplicated falciparum malaria.","volume":"6","author":"Winstanley","year":"2001","journal-title":"Trop Med Int Health"},{"issue":"9424","key":"2019111809170678700_B17","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(04)16350-2","article-title":"Comparison of chlorproguanil-dapsone with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in young African children: double-blind randomised controlled trial.","volume":"363","author":"Alloueche","year":"2004","journal-title":"Lancet"},{"key":"2019111809170678700_B18","unstructured":"World Health Organization Review of the safety of chlorproguanil-dapsone in the treatment of uncomplicated falciparum malaria in Africa: report of a technical consultation convened by WHO, Geneva, Switzerland, 1-2 July 2004. Accessed May 2, 2011 http:\/\/www.who.int\/malaria\/publications\/atoz\/who_htm_mal_2005_1106\/en\/"},{"issue":"9742","key":"2019111809170678700_B19","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0140-6736(10)60396-0","article-title":"The rise and fall of the antimalarial Lapdap: a lesson in pharmacogenetics.","volume":"376","author":"Luzzatto","year":"2010","journal-title":"Lancet"},{"issue":"4","key":"2019111809170678700_B20","first-page":"401","article-title":"Haemoglobinuria after a single dose treatment with dapsone and pyrimethamine for falciparum malaria in a patient with glucose-6-phosphate dehydrogenase deficiency.","volume":"33","author":"Ponnampalam","year":"1981","journal-title":"Trop Geogr Med"},{"issue":"2","key":"2019111809170678700_B21","first-page":"165","article-title":"The haemolytic effects of diaphenylsulfone (DDS) in normal subjects and in those with glucose-6-phosphate-dehydrogenase deficiency.","volume":"35","author":"Degowin","year":"1966","journal-title":"Bull World Health Organ"},{"issue":"8","key":"2019111809170678700_B22","doi-asserted-by":"crossref","first-page":"e6682","DOI":"10.1371\/journal.pone.0006682","article-title":"Chlorproguanil-dapsone-artesunate versus artemether-lumefantrine: a randomized, double-blind phase III trial in African children and adolescents with uncomplicated Plasmodium falciparum malaria.","volume":"4","author":"Premji","year":"2009","journal-title":"PLoS One"},{"issue":"6","key":"2019111809170678700_B23","doi-asserted-by":"crossref","first-page":"969","DOI":"10.4269\/ajtmh.2009.09-0351","article-title":"Chlorproguanil-dapsone-artesunate versus chlorproguanil-dapsone: a randomized, double-blind, phase III trial in African children, adolescents, and adults with uncomplicated Plasmodium falciparum malaria.","volume":"81","author":"Tiono","year":"2009","journal-title":"Am J Trop Med Hyg"},{"key":"2019111809170678700_B24","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/1475-2875-10-241","article-title":"Frequency of glucose-6-phosphate dehydrogenase deficiency in malaria patients from six African countries enrolled in two randomized anti-malarial clinical trials.","volume":"10","author":"Carter","year":"2011","journal-title":"Malar J"},{"key":"2019111809170678700_B25","unstructured":"World Health Organization Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria (WHO\/HTM\/RBM\/2003.50). Accessed March 27, 2011 http:\/\/whqlibdoc.who.int\/hq\/2003\/WHO_HTM_RBM_2003.50.pdf"},{"issue":"4","key":"2019111809170678700_B26","first-page":"220","article-title":"Clinical and laboratory findings in acute malaria caused by various plasmodium species.","volume":"59","author":"Rasheed","year":"2009","journal-title":"J Pak Med Assoc"},{"issue":"1","key":"2019111809170678700_B27","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2141.1985.tb02976.x","article-title":"Membrane cross bonding in red cells in favic crisis: a missing link in the mechanism of extravascular haemolysis.","volume":"59","author":"Fischer","year":"1985","journal-title":"Br J Haematol"},{"key":"2019111809170678700_B28","first-page":"1921","article-title":"Glucose-6-phosphate dehydrogenase deficiency and related disorders.","volume-title":"Blood: Principles and Practice of Hematology","author":"Vulliamy","year":"2003","edition":"2nd Ed"},{"issue":"3","key":"2019111809170678700_B29","first-page":"439","article-title":"The hemolytic effect of primaquine. IV. The relationship of cell age to hemolysis.","volume":"44","author":"Beutler","year":"1954","journal-title":"J Lab Clin Med"},{"issue":"2","key":"2019111809170678700_B30","first-page":"171","article-title":"The hemolytic effect of primaquine. II. The natural course of the hemolytic anemia and the mechanism of its self-limited character.","volume":"44","author":"Dern","year":"1954","journal-title":"J Lab Clin Med"},{"issue":"7","key":"2019111809170678700_B31","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1182\/blood.V74.7.2550.2550","article-title":"Molecular heterogeneity of glucose-6-phosphate dehydrogenase A.","volume":"74","author":"Beutler","year":"1989","journal-title":"Blood"},{"key":"2019111809170678700_B32","unstructured":"World Health Organization Hemoglobin concentrations for the diagnosis of anemia and assessment of severity. Accessed May 15, 2011 http:\/\/www.who.int\/vmnis\/indicators\/haemoglobin.pdf"},{"issue":"5","key":"2019111809170678700_B33","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1590\/S0037-86822002000500005","article-title":"Adverse effects of multidrug therapy in leprosy patients: a five-year survey at a Health Center of the Federal University of Uberlandia [in Portuguese].","volume":"35","author":"Goulart","year":"2002","journal-title":"Rev Soc Bras Med Trop"},{"issue":"3","key":"2019111809170678700_B34","doi-asserted-by":"crossref","first-page":"216","DOI":"10.47276\/lr.78.3.216","article-title":"Adverse effects from multi-drug therapy in leprosy: a Brazilian study.","volume":"78","author":"Deps","year":"2007","journal-title":"Lepr Rev"},{"issue":"1","key":"2019111809170678700_B35","doi-asserted-by":"crossref","first-page":"17","DOI":"10.47276\/lr.82.1.17","article-title":"Adverse effects of multi-drug therapy in leprosy, a two years' experience (2006-2008) in tertiary health care centre in the tribal region of Chhattisgarh state (Bastar, Jagdalpur).","volume":"82","author":"Singh","year":"2011","journal-title":"Lepr Rev"},{"issue":"6","key":"2019111809170678700_B36","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1365-2125.1995.tb05797.x","article-title":"N-hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity.","volume":"40","author":"Gill","year":"1995","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"2019111809170678700_B37","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1365-2125.1989.tb03517.x","article-title":"Bioactivation of dapsone to a cytotoxic metabolite by human hepatic microsomal enzymes.","volume":"28","author":"Coleman","year":"1989","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"2019111809170678700_B38","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1111\/j.1476-5381.2010.00962.x","article-title":"Dapsone hydroxylamine induces premature removal of human erythrocytes by membrane reorganization and antibody binding.","volume":"161","author":"Bordin","year":"2010","journal-title":"Br J Pharmacol"},{"key":"2019111809170678700_B39","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1101\/SQB.1964.029.01.043","article-title":"Genetic tests with a sex-linked marker: glucose-6-phosphate dehydrogenase.","volume":"29","author":"Nance","year":"1964","journal-title":"Cold Spring Harb Symp Quant Biol"},{"issue":"5","key":"2019111809170678700_B40","first-page":"496","article-title":"Variability of red cell phenotypes between and within individuals in an unbiased sample of 77 heterozygotes for G6PD deficiency in Sardinia.","volume":"28","author":"Rinaldi","year":"1976","journal-title":"Am J Hum Genet"},{"issue":"2","key":"2019111809170678700_B41","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000206700","article-title":"Favism and hemolytic anemia in glucose-6-phosphate dehydrogenase\u2013deficient subjects in North Sardinia.","volume":"70","author":"Meloni","year":"1983","journal-title":"Acta Haematol"},{"issue":"8","key":"2019111809170678700_B42","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1586\/eri.09.68","article-title":"Discovery, mechanisms of action and combination therapy of artemisinin.","volume":"7","author":"Cui","year":"2009","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"1-3","key":"2019111809170678700_B43","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0014-5793(03)01448-0","article-title":"Alkylation of human hemoglobin A0 by the antimalarial drug artemisinin.","volume":"556","author":"Selmeczi","year":"2004","journal-title":"FEBS Lett"},{"key":"2019111809170678700_B44","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1475-2875-11-91","article-title":"Haemolytic anaemia in an HIV-infected patient with severe falciparum malaria after treatment with oral artemether-lumefantrine.","volume":"11","author":"Corpolongo","year":"2012","journal-title":"Malar J"},{"issue":"5","key":"2019111809170678700_B45","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1365-3156.2004.01237.x","article-title":"Rapid epidemiologic assessment of glucose-6-phosphate dehydrogenase deficiency in malaria-endemic areas in Southeast Asia using a novel diagnostic kit.","volume":"9","author":"Jalloh","year":"2004","journal-title":"Trop Med Int Health"},{"key":"2019111809170678700_B46","first-page":"5","article-title":"Standardization of procedures for the study of glucose-6-phosphate dehydrogenase: report of a WHO Scientific Group.","volume":"366","author":"Betke","year":"1967","journal-title":"World Health Org Tech Rep Ser"},{"key":"2019111809170678700_B47","first-page":"83","article-title":"Hemolytic side effects on some antimalarial drugs.","volume":"39","author":"Salvidio","year":"1972","journal-title":"Proc Hemlinth Soc Washington"},{"issue":"5","key":"2019111809170678700_B48","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s12185-011-0827-6","article-title":"Unsuspected glucose-6-phosphate dehydrogenase deficiency presenting as symptomatic methemoglobinemia with severe hemolysis after fava bean ingestion in a 6-year-old boy.","volume":"93","author":"Odi\u00e8vre","year":"2011","journal-title":"Int J Hematol"},{"issue":"1","key":"2019111809170678700_B49","first-page":"71","article-title":"Glucose-6-phosphate dehydrogenase (G6PD) deficiency in southern Italy: a case of G6PD A(\u2212) associated with favism.","volume":"74","author":"Calabr\u00f2","year":"1989","journal-title":"Haematologica"},{"issue":"6719","key":"2019111809170678700_B50","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1136\/bmj.300.6719.236","article-title":"Favism in the African type of glucose-6-phosphate dehydrogenase deficiency (A\u2212).","volume":"300","author":"Galiano","year":"1990","journal-title":"Br Med J"},{"issue":"4","key":"2019111809170678700_B51","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/ajh.21660","article-title":"A ghostly presence-G6PD deficiency.","volume":"85","author":"Bain","year":"2010","journal-title":"Am J Hematol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/20\/4123\/1359986\/zh804612004123.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/20\/4123\/1359986\/zh804612004123.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T06:36:17Z","timestamp":1643438177000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/120\/20\/4123\/30568\/Clinical-spectrum-and-severity-of-hemolytic-anemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,15]]},"references-count":51,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2012,11,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-03-416032","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717958918.793463587","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,15]]}}}